Form 4: Day One Biopharmaceuticals Director Acquires Stock Options

Michael Gladstone, a director at Day One Biopharmaceuticals, acquired stock options for 32,335 shares on May 23, 2024.

Summary

• Michael Gladstone, a director of Day One Biopharmaceuticals, Inc. (DAWN), filed a Form 4.
• On May 23, 2024, Gladstone acquired stock options for 32,335 shares of common stock at an exercise price of $13.87.
• The options vest in monthly installments starting June 23, 2024, and expire on May 22, 2034.
• Following the transaction, Gladstone directly owns options for 32,335 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be seen as a slightly positive sign of confidence but doesn't provide significant information about the company's overall performance.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard SEC filing related to insider transactions. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation packages.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their directors and officers.
• The vesting schedule and exercise price are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates